Q3 EPS Forecast for Denali Therapeutics Increased by Analyst

Key Points

• B. Riley Research has raised its Q3 2025 EPS estimate for Denali Therapeutics from ($0.86) to ($0.79), expecting a total FY2025 earnings of ($3.08) EPS.
• Denali Therapeutics reported a Q2 loss of ($0.72) EPS, slightly beating analysts' expectations of ($0.74).
• Current coverage shows a majority of analysts giving Denali Therapeutics a "Buy" rating, with a consensus price target of $33.85.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at B. Riley upped their Q3 2025 earnings estimates for Denali Therapeutics in a report released on Wednesday, August 13th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.79) per share for the quarter, up from their prior forecast of ($0.86). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics' Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.08) EPS, FY2026 earnings at ($2.68) EPS, FY2027 earnings at ($1.66) EPS and FY2028 earnings at ($2.47) EPS.

Several other research analysts have also weighed in on the stock. HC Wainwright cut their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Bank of America cut their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. TD Cowen upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Finally, Wedbush cut their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $33.62.

Denali Therapeutics Trading Up 1.7%

Shares of DNLI stock traded up $0.26 during trading hours on Monday, hitting $15.49. 2,743,895 shares of the company were exchanged, compared to its average volume of 1,740,341. The firm has a market cap of $2.26 billion, a PE ratio of -5.53 and a beta of 1.36. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $33.33. The company has a quick ratio of 10.27, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $14.31 and a 200 day moving average of $15.08.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the previous year, the company earned ($0.59) EPS.

Insider Activity at Denali Therapeutics

In related news, insider Carole Ho sold 2,937 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the sale, the insider directly owned 217,391 shares in the company, valued at approximately $2,952,169.78. This trade represents a 1.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander O. Schuth sold 2,937 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the sale, the insider owned 242,346 shares in the company, valued at approximately $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 501,962 shares of company stock worth $7,520,799. 12.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd increased its holdings in Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after purchasing an additional 1,551 shares during the last quarter. State of Wyoming purchased a new stake in Denali Therapeutics during the 2nd quarter worth approximately $29,000. Sterling Capital Management LLC increased its holdings in Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after purchasing an additional 1,516 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Denali Therapeutics during the 1st quarter worth approximately $41,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.